Renaissance Technologies
TVTX icon

Renaissance Technologies’s Travere Therapeutics TVTX Stock Holding History

Renaissance Technologies’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.4M Sell
1,966,779
-280,000
-12% -$8.37M 0.09% 277
2025
Q4 		$85.8M Buy
2,246,779
+494,665
+28% +$16.1M 0.13% 176
2025
Q3 		$41.9M Sell
1,752,114
-743,000
-30% -$14M 0.06% 421
2025
Q2 		$36.9M Sell
2,495,114
-207,700
-8% -$3.44M 0.05% 451
2025
Q1 		$48.4M Buy
2,702,814
+293,300
+12% +$5.95M 0.07% 331
2024
Q4 		$42M Buy
2,409,514
+534,500
+29% +$9.45M 0.06% 381
2024
Q3 		$26.2M Sell
1,875,014
-328,800
-15% -$3.43M 0.04% 548
2024
Q2 		$18.1M Sell
2,203,814
-658,200
-23% -$4.43M 0.03% 639
2024
Q1 		$22.1M Sell
2,862,014
-219,000
-7% -$1.85M 0.03% 586
2023
Q4 		$27.7M Buy
3,081,014
+1,086,892
+55% +$7.91M 0.04% 489
2023
Q3 		$17.8M Buy
1,994,122
+439,109
+28% +$6.2M 0.03% 622
2023
Q2 		$23.9M Sell
1,555,013
-589,809
-27% -$10.7M 0.03% 592
2023
Q1 		$48.2M Buy
2,144,822
+551,300
+35% +$11.7M 0.06% 361
2022
Q4 		$33.5M Buy
1,593,522
+86,100
+6% +$1.82M 0.05% 478
2022
Q3 		$37.1M Sell
1,507,422
-149,600
-9% -$3.87M 0.05% 414
2022
Q2 		$40.1M Buy
1,657,022
+299,700
+22% +$7.54M 0.05% 430
2022
Q1 		$35M Buy
1,357,322
+317,400
+31% +$8.43M 0.04% 475
2021
Q4 		$32.3M Sell
1,039,922
-200,496
-16% -$5.65M 0.04% 480
2021
Q3 		$30.1M Sell
1,240,418
-470,904
-28% -$8.65M 0.04% 487
2021
Q2 		$25M Buy
1,711,322
+122,600
+8% +$2.42M 0.03% 620
2021
Q1 		$39.7M Sell
1,588,722
-272,700
-15% -$7.53M 0.05% 449
2020
Q4 		$50.7M Sell
1,861,422
-95,732
-5% -$2.24M 0.06% 349
2020
Q3 		$36.1M Sell
1,957,154
-21,334
-1% -$415K 0.04% 485
2020
Q2 		$40.4M Buy
1,978,488
+779,700
+65% +$12.4M 0.03% 495
2020
Q1 		$17.5M Buy
1,198,788
+381,961
+47% +$5.75M 0.02% 845
2019
Q4 		$11.6M Buy
816,827
+135,902
+20% +$1.74M 0.01% 1350
2019
Q3 		$7.89M Buy
680,925
+414,625
+156% +$6.85M 0.01% 1534
2019
Q2 		$5.35M Buy
266,300
+132,100
+98% +$2.61M ﹤0.01% 1777
2019
Q1 		$3.04M Buy
+134,200
New +$2.97M ﹤0.01% 2105
2018
Q2 		– Sell
-138,200
Closed -$3.09M – 3534
2018
Q1 		$3.09M Buy
+138,200
New +$3.29M ﹤0.01% 2088
2017
Q2 		– Sell
-364,800
Closed -$6.73M – 3368
2017
Q1 		$6.73M Buy
364,800
+323,500
+783% +$6.33M 0.01% 1503
2016
Q4 		$782K Buy
+41,300
New +$845K ﹤0.01% 2633
2016
Q2 		– Sell
-76,600
Closed -$1.05M – 3510
2016
Q1 		$1.05M Buy
+76,600
New +$1.16M ﹤0.01% 2566
2015
Q4 		– Sell
-100,913
Closed -$2.04M – 3433
2015
Q3 		$2.04M Buy
100,913
+20,413
+25% +$605K ﹤0.01% 1975
2015
Q2 		$2.67M Buy
+80,500
New +$2.2M 0.01% 1867

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Renaissance Technologies's TVTX Position: Q1 2026 in Review

Renaissance Technologies reduced its Travere Therapeutics (TVTX) stake by 12% in Q1 2026, selling an estimated $8.37M and leaving 1,966,779 shares worth $58.4M. The position accounts for 0.09% of the portfolio, ranked #277.

Renaissance Technologies first reported a position in TVTX in Q2 2015 and has held it in 35 quarters since. The position peaked at $85.8M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Renaissance Technologies held 1,966,779 shares of Travere Therapeutics worth $58.4M as of Q1 2026.
  • Renaissance Technologies sold 280,000 Travere Therapeutics shares in Q1 2026, an estimated $8.37M.
  • Travere Therapeutics made up 0.09% of Renaissance Technologies's portfolio in Q1 2026, its #277 holding.
  • Renaissance Technologies first reported a position in Travere Therapeutics in Q2 2015 and has held it in 35 quarters since.
  • Renaissance Technologies's Travere Therapeutics position peaked at $85.8M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.